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Background
We have for the first time evaluated whether a partially
hydrolysed whey based (pHF) formula combined with spe-
cific mixture of prebiotic oligosaccharides would reduce
the risk of allergic manifestations (AM) in formula-fed
infants at increased risk of allergy.
Methods
We recruited term, healthy newborn infants from 10
centres in Australia, Singapore, England and Ireland.
They had at least one parent with allergic disease and
were randomised to receive a pHF-prebiotic formula
(active; 432) or standard cow’s milk formula (control;
431) for the first 26 weeks of life if parents decided to
stop or supplement breastfeeding < 18 weeks. 324
infants were followed up for occurrence of AM until 3-5
years (ISRCTN65195597).
Primary outcome was cumulative incidence of atopic
dermatitis (AD) up to 12 months in the key group of
interest (KGI), which consisted of those infants that
started formula < 28 days of age (active 375; control
383). Secondary and post-hoc outcomes are reported on
all subjects randomised.
Results
In the KGI, AD developed in 93/324 (29%) infants rando-
mised to control and 84/293 (29%) to active (OR 0.94 -
[95%CI 0.65-1.36]). We found no difference in AM at 3-5
years. The active group had lower serum cow’s milk (CM)
IgG1 at 6 months than the control (p<0.0001) and this dif-
ference was still observed at 3 years (p=0.007). Higher
CM-IgG1 levels at 6 months were significantly associated
with development of specific IgE (CM, hen’s egg) at 3
years (p<0.05). We found no difference between groups in
adverse events.
Post-hoc analyses were performed on infants who
had not introduced solids < 18 weeks (n=312). In this
subgroup, active formula was associated with reduced
AM at 3-5 years (n=144; p=0.0334) and lower levels of
total-IgE and hen’s egg IgE at 6 months (n=239,
p=0.0092 and n=244, p=0.0061) compared with control
group.
Conclusion
Early feeding with a pHF-prebiotic formula was not asso-
ciated with a reduced risk of AD at 12 months or AM at
3-5 years. The pHF-prebiotic formula use did show a per-
sistent immune-modulatory effect and possibly a reduced
occurrence of AM in infants who introduced solids
according to guidelines (> 18 weeks).
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